Lipigon Pharmaceuticals AB, which develops new treatments for lipid-related diseases, announces that the board has elected Urban Paulsson as the new chairman of the board. Paulsson was elected to the board on October 30, 2020 and now replaces Carina Schmidt, who requested her own resignation from the board.
At an Extraordinary General Meeting, Urban Paulsson was elected a regular board member of Umeå-based Lipigon Pharmaceuticals AB. Urban Paulsson’s business law expertise entails a strengthening of the Board and is an important component for the company’s continued successful development.
Umeå-based Lipigon Pharmaceuticals has signed agreements with universities in Shanghai and Shenzhen to develop a new drug that can potentially reduce the number of deaths linked to Covid-19.
“Right now there are very few treatments available for Acute Respiratory Distress Syndrome (ARDS), which can be fatal to some Covid-19 patients. The standard treatment is oxygen and the use of respirators. We hope to change that,” says Lipogon’s CEO, Stefan K Nilsson.
Umeå-based Lipigon Pharmaceuticals has attracted SEK 16.6 Million in a new share issue that will help it get nearer to its goal of reducing the number of global deaths caused by cardiovascular disease.
“We are extremely proud our new shares issue was oversubscribed, particularly during the ongoing Coronavirus pandemic when many investors are feeling more cautious. It is an indication of the level of belief in us,” says Stefan K Nilsson, CEO of Lipigon.
Umeå-based Lipigon Pharmaceuticals AB has signed a major new agreement with Chinese biotech company HitGen to develop drug candidates that treat blood fat disorders and cardiovascular diseases.
“We want to create effective treatments and contribute to a better quality of life for patients,” says Stefan K Nilsson, CEO of Lipigon.
Umeå-based Lipigon Pharmaceuticals has signed a new deal and taken over the patent portfolio for a number of drug candidates that could help treat cardiovascular diseases.
“The market in treatments for various blood fat disorders amounts to several billion dollars. This is a very important opportunity for us,” says Stefan K Nilsson, CEO of Lipigon.
Life science company Lipigon Pharmaceuticals has recruited two new members of staff following the signing of a multi-million SEK agreement for its gene therapy project with listed Nordic company CombiGene.
The new appointments will bring additional knowledge and skills to the Umeå-based company that will help it reach project milestones in the years ahead.
“This agreement allows us to grow, which is great for us and for Umeå,” says Stefan K Nilsson, CEO of Lipigon.
Life science company Lipigon Pharmaceuticals has signed an agreement for its gene therapy project with listed company CombiGene.
“If everything goes well this agreement could potentially be worth millions. But it also enables us to develop our business in the short term, not least because we can now employ highly competent staff in Umeå,” says Stefan K Nilsson, CEO of Lipigon.